Genome-wide association study: A useful tool to identify common genetic variants associated with drug toxicity and efficacy in cancer pharmacogenomics

Siew Kee Low, Atsushi Takahashi, Taisei Mushiroda, Michiaki Kubo

研究成果: Article

27 引用 (Scopus)

抄録

In recent years, the utilization of genome-wide association study (GWAS) has proved to be a beneficial method to identify novel common genetic variations not only for disease susceptibility but also for drug efficacy and drug-induced toxicity, creating a field of pharmacogenomics studies. In addition, the findings from GWAS also generate new biologic hypotheses that could improve the understanding of pathophysiology for disease or the mechanism of drug-induced toxicity. This review highlights the implications of GWAS that have been published to date and discusses the successes as well as challenges of using GWAS in cancer pharmacogenomics. The aim of pharmacogenomics is to realize the vision of personalized medicine; it is hoped that through GWAS, novel common genetic variations could be identified to predict clinical outcome and/or toxicity in cancer therapies that subsequently could be implemented to improve the quality of lives of patients with cancer. Nevertheless, given the complexity of cancer therapies, underpowered studies, and large heterogeneity of study designs, collaborative efforts are needed to validate these findings and overcome the limitations of GWA studies before clinical implementation.

元の言語English
ページ(範囲)2541-2552
ページ数12
ジャーナルClinical Cancer Research
20
発行部数10
DOI
出版物ステータスPublished - 15-05-2014

Fingerprint

Genome-Wide Association Study
Pharmacogenetics
Drug-Related Side Effects and Adverse Reactions
Neoplasms
Precision Medicine
Disease Susceptibility
Therapeutics
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

これを引用

@article{cee9f630ed014912bfcf5f572fe2889e,
title = "Genome-wide association study: A useful tool to identify common genetic variants associated with drug toxicity and efficacy in cancer pharmacogenomics",
abstract = "In recent years, the utilization of genome-wide association study (GWAS) has proved to be a beneficial method to identify novel common genetic variations not only for disease susceptibility but also for drug efficacy and drug-induced toxicity, creating a field of pharmacogenomics studies. In addition, the findings from GWAS also generate new biologic hypotheses that could improve the understanding of pathophysiology for disease or the mechanism of drug-induced toxicity. This review highlights the implications of GWAS that have been published to date and discusses the successes as well as challenges of using GWAS in cancer pharmacogenomics. The aim of pharmacogenomics is to realize the vision of personalized medicine; it is hoped that through GWAS, novel common genetic variations could be identified to predict clinical outcome and/or toxicity in cancer therapies that subsequently could be implemented to improve the quality of lives of patients with cancer. Nevertheless, given the complexity of cancer therapies, underpowered studies, and large heterogeneity of study designs, collaborative efforts are needed to validate these findings and overcome the limitations of GWA studies before clinical implementation.",
author = "Low, {Siew Kee} and Atsushi Takahashi and Taisei Mushiroda and Michiaki Kubo",
year = "2014",
month = "5",
day = "15",
doi = "10.1158/1078-0432.CCR-13-2755",
language = "English",
volume = "20",
pages = "2541--2552",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

Genome-wide association study : A useful tool to identify common genetic variants associated with drug toxicity and efficacy in cancer pharmacogenomics. / Low, Siew Kee; Takahashi, Atsushi; Mushiroda, Taisei; Kubo, Michiaki.

:: Clinical Cancer Research, 巻 20, 番号 10, 15.05.2014, p. 2541-2552.

研究成果: Article

TY - JOUR

T1 - Genome-wide association study

T2 - A useful tool to identify common genetic variants associated with drug toxicity and efficacy in cancer pharmacogenomics

AU - Low, Siew Kee

AU - Takahashi, Atsushi

AU - Mushiroda, Taisei

AU - Kubo, Michiaki

PY - 2014/5/15

Y1 - 2014/5/15

N2 - In recent years, the utilization of genome-wide association study (GWAS) has proved to be a beneficial method to identify novel common genetic variations not only for disease susceptibility but also for drug efficacy and drug-induced toxicity, creating a field of pharmacogenomics studies. In addition, the findings from GWAS also generate new biologic hypotheses that could improve the understanding of pathophysiology for disease or the mechanism of drug-induced toxicity. This review highlights the implications of GWAS that have been published to date and discusses the successes as well as challenges of using GWAS in cancer pharmacogenomics. The aim of pharmacogenomics is to realize the vision of personalized medicine; it is hoped that through GWAS, novel common genetic variations could be identified to predict clinical outcome and/or toxicity in cancer therapies that subsequently could be implemented to improve the quality of lives of patients with cancer. Nevertheless, given the complexity of cancer therapies, underpowered studies, and large heterogeneity of study designs, collaborative efforts are needed to validate these findings and overcome the limitations of GWA studies before clinical implementation.

AB - In recent years, the utilization of genome-wide association study (GWAS) has proved to be a beneficial method to identify novel common genetic variations not only for disease susceptibility but also for drug efficacy and drug-induced toxicity, creating a field of pharmacogenomics studies. In addition, the findings from GWAS also generate new biologic hypotheses that could improve the understanding of pathophysiology for disease or the mechanism of drug-induced toxicity. This review highlights the implications of GWAS that have been published to date and discusses the successes as well as challenges of using GWAS in cancer pharmacogenomics. The aim of pharmacogenomics is to realize the vision of personalized medicine; it is hoped that through GWAS, novel common genetic variations could be identified to predict clinical outcome and/or toxicity in cancer therapies that subsequently could be implemented to improve the quality of lives of patients with cancer. Nevertheless, given the complexity of cancer therapies, underpowered studies, and large heterogeneity of study designs, collaborative efforts are needed to validate these findings and overcome the limitations of GWA studies before clinical implementation.

UR - http://www.scopus.com/inward/record.url?scp=84901021796&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901021796&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-13-2755

DO - 10.1158/1078-0432.CCR-13-2755

M3 - Article

C2 - 24831277

AN - SCOPUS:84901021796

VL - 20

SP - 2541

EP - 2552

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 10

ER -